E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Active immunization against tetanus, diphtheria and pertussis |
|
E.1.1.1 | Medical condition in easily understood language |
Protection against tetanus, diphtheria and pertussis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10054129 |
E.1.2 | Term | Diphtheria immunisation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10069577 |
E.1.2 | Term | Pertussis immunisation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10054131 |
E.1.2 | Term | Tetanus immunisation |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1) To compare the diphtheria and tetanus seroprotection rates in Group 1 and Group 2 approximately one month post Tdap-vaccination
2) To compare the pertussis antibody geometric mean concentrations (GMCs) in
Group 1 and Group 2 approximately one month post Tdap-vaccination |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Group 1 and Group 2
1) For Group 1: received Tdap or Tdap-IPV vaccine in study TD9707 or TD9805.
For Group 2: never previously received Tdap vaccine and has not received any tetanus-, diphtheria-, or pertussis-containing vaccine in the past 10 years
2) Signed Institutional Review Board (IRB)-approved informed consent form
3) Able to attend all scheduled visits and to comply with all trial procedures
4) For a woman, a negative urine pregnancy test and the use of effective method(s) of contraception or the inability to become pregnant
Group 3
1) Participated in TD9707* or TD9805 but does not meet inclusion/exclusion criteria for Group 1, or willing to undergo phlebotomy but not willing to receive Tdap (ADACEL) vaccine
2) Signed Institutional Review Board (IRB)-approved informed consent form
* Past TD9707 study subjects will qualify for this group, if they were originally enrolled at the two study centers that participated in the 3- and 5-year long-term immunogenicity follow-ups. |
|
E.4 | Principal exclusion criteria |
An individual fulfilling any of the following criteria is to be excluded from trial enrollment:
Group 1 and Group 2
1) Any condition listed as a contraindication in the ADACEL Canadian product monograph
2) Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine
3) Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator
4) Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic (injected or oral) corticosteroid therapy. Individuals on a tapering dose schedule of oral steroids lasting less than 7 days may be included in the trial as long as they have not received more than 1 course within the last 2 weeks prior to enrollment
5) Febrile illness (temperature ≥ 37.5°C [99.5°F]) at the time of inclusion
6) For Group 1, history of documented diphtheria, pertussis, or tetanus disease since participation in studies TD9707 or TD9805. For Group 2, history of documented diphtheria, pertussis, or tetanus disease in the last 10 years.
7) For Group 1, known or suspected receipt of a diphtheria-, pertussis-, or tetanus containing vaccine since participation in study TD9707 or TD9805. For Group 2, known or suspected receipt of a diphtheria-, pertussis-, or tetanus-containing vaccine in the last 10 years.
8) Receipt of any vaccine, other than influenza vaccine, in the 28-day period prior to V1 or scheduled to receive any vaccine, other than influenza vaccine, in the period between V1 and V2. For influenza vaccine only, defer if received in the 14 days prior to enrollment or scheduled to receive prior to V2.
9) Receipt of blood or blood-derived products in the past 3 months
10) Suspected or known hypersensitivity to any of the vaccine components, or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances
11) Unable to attend the scheduled visits or to comply with the study procedures
12) In females of childbearing potential, known pregnancy or positive serum/urine pregnancy test
13) Breast-feeding woman
14) Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding enrollment. Planned participation in another clinical trial during the present trial period.
15) Current alcohol or recreational drug use that may interfere with the subject's ability to comply with trial procedures
16) Thrombocytopenia, bleeding disorder, anticoagulation therapy contraindicating IM vaccination
17) Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
Temporary Exclusion Criteria:
Should the following conditions occur, the investigator will postpone vaccination until the condition is resolved. Enrollment may occur if the condition is resolved and enrollment is still open.
18) Febrile illness (temperature ≥ 37.5°C [99.5°F]) at the time of inclusion. See Exclusion #5.)
19) Short term systemic (injected or oral) corticosteroid therapy. (See Exclusion #4.) Individuals on a tapering dose schedule of oral steroids lasting less than 7 days may be included in the trial as long as they have not received more than 1 course within the last 2 weeks prior to enrollment.
20) Receipt of vaccine, other than influenza, in the 28-day period prior to V1. Receipt of influenza vaccine in the 14-day period prior to V1. (See Exclusion #8).
21) Other events which in the judgment of the investigator would preclude vaccination at the time of V1
Group 3
1) History of documented diphtheria, pertussis, or tetanus disease since participation in study TD9707 or TD9805
2) Known or suspected receipt of a diphtheria-, pertussis-, or tetanus-containing vaccine since participation in study TD9707 or TD9805 |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1) Anti-diphtheria and anti-tetanus antitoxin concentrations post-vaccination (Visit 2), measured using a microneutralization assay and an enzyme-linked immunosorbent assay (ELISA), respectively, and expressed as proportions with antitoxin concentrations ≥ 0.10 IU/mL
2) Anti-pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], pertactin [PRN], fimbriae types 2 and
3 [FIM]) antibody concentrations post-vaccination, measured using an ELISA, and expressed as geometric mean concentrations (GMCs) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Post-Vaccination (Visit 2):
Anti-diphtheria and anti-tetanus antitoxin concentrations
Post-Vaccination:
Anti-pertussis (pertussis toxoid [PT], filamentous hemagglutinin [FHA], pertactin [PRN], fimbriae types 2 and 3 [FIM]) antibody concentrations |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |